Equities Analysts Set Expectations for PROF Q1 Earnings

Profound Medical Corp. (NASDAQ:PROF) – Research analysts at Raymond James issued their Q1 2026 earnings estimates for shares of Profound Medical in a report released on Tuesday, February 18th. Raymond James analyst M. Freeman forecasts that the company will post earnings per share of ($0.24) for the quarter. Raymond James currently has a “Strong-Buy” rating on the stock. The consensus estimate for Profound Medical’s current full-year earnings is ($1.15) per share. Raymond James also issued estimates for Profound Medical’s Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.19) EPS and Q4 2026 earnings at ($0.14) EPS.

Profound Medical Stock Performance

Shares of PROF stock opened at $6.79 on Wednesday. The company’s fifty day simple moving average is $7.02 and its 200-day simple moving average is $7.76. Profound Medical has a 52 week low of $5.63 and a 52 week high of $11.42. The company has a debt-to-equity ratio of 0.11, a current ratio of 6.12 and a quick ratio of 5.16.

Institutional Investors Weigh In On Profound Medical

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Stonepine Capital Management LLC purchased a new stake in Profound Medical during the 4th quarter worth $1,502,000. Maven Securities LTD purchased a new stake in Profound Medical during the 4th quarter worth $376,000. Letko Brosseau & Associates Inc. increased its stake in Profound Medical by 1.0% during the 4th quarter. Letko Brosseau & Associates Inc. now owns 1,211,150 shares of the company’s stock worth $8,689,000 after buying an additional 12,375 shares during the period. Bleichroeder LP increased its stake in Profound Medical by 37.5% during the 4th quarter. Bleichroeder LP now owns 183,333 shares of the company’s stock worth $1,377,000 after buying an additional 50,000 shares during the period. Finally, Alyeska Investment Group L.P. purchased a new stake in Profound Medical during the 4th quarter worth $1,202,000. Hedge funds and other institutional investors own 47.86% of the company’s stock.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.